Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
TARGET-ALL-P2
Acute Lymphoblastic Leukemia - Phase II
0 awards paid to create it · 38 awards funded work that used it
1. Awards that paid to create this data
2. The dataset
3. Articles that used it (6 of 8)
- Ma et al. · Nature · 2018797 citations
- Liu et al. · Nature genetics · 2017791 citations
- Li et al. · Proceedings of the National Academy of Sciences of the United States of America · 2018255 citations
- Pölönen et al. · Nature · 2024130 citations
- Gocho et al. · Nature cancer · 2021120 citations
- Oshima et al. · Nature cancer · 202062 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 38)
- Translating genomic discoveries to improved outcomes for high risk acute leukem… · Charles G Mullighan · FY2017–2026funded 2 of these 8 articles
- PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL) · WILLIAM E EVANS · FY1987–2014funded 2 of these 8 articles
- Cancer Biology (CBP) · Douglas R. Green, Michael A Dyer · FY1985–2026funded 5 of these 8 articles
- Children's Oncology Group Chair's Grant · PETER C. ADAMSON, GREGORY H REAMAN · FY2003–2013funded 3 of these 8 articles
- Children's Oncology Group Statistics and Data Center · TODD A ALONZO, Meenakshi Devidas · FY2014–2026funded 3 of these 8 articles
- Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) · Nilsa Del Carmen Ramirez Milan, GREGORY H REAMAN · FY2005–2014funded 3 of these 8 articles
The best connected are shown.
Direct evidence: the award is on the paper, or the accession is in the articleWeaker: infrastructure support, or use declared but not shownHover any card to follow its chain
Why one side of this chain is empty
- No repository or reviewer names this dataset's marker paper, so no award can be credited with creating it.
Awards that funded work using this data
8 of 10 traced articles report an NCI award.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| P30CA016058 P30FY1985–2026$258.1M | Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR) | API | |
| U01CA157937 U01FY2011–2015$2.9M | MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL | API | |
| R35CA197695 R35FY2017–2026$11.4M | Translating genomic discoveries to improved outcomes for high risk acute leukemia | API | |
| R01CA036401 R01FY1985–2019$4.0M | Pharmacogenomics of Childhood Leukemia ALL | API | |
| R37CA036401 R37FY1987–2014$13.3M | PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL) | API | |
| F32CA254140 F32FY2020–2022$152k | Role of WT1 in mixed phenotype acute leukemia | API | |
| K08CA286762 K08FY2024–2026$746k | Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS | API | |
| K12CA076931 K12FY1997–2026$17.6M | Physician Scientist Training in Clinical Oncology | API | |
| K99CA279756 K99FY2023–2024$272k | Role of BCL11B in lineage ambiguous leukemia | API | |
| R01CA193776 R01FY2015–2026$6.2M | Improving risk allocation and developing novel therapies for children with T-ALL and T-LL | API | |
| R01CA264837 R01FY2021–2025$3.0M | Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | API | |
| R03CA256550 R03FY2021$382k | Genomic Profiling of T-cell Acute Lymphoblastic Leukemia in Children | API | |
| T32CA009615 T32FY1988–2026$12.7M | Cancer Center Research Training Program | API | |
| T32CA236748 T32FY2019–2026$2.0M | Childhood Hematological Malignancies Training Program | API | |
| U54CA243124 U54FY2019–2023$20.9M | Experimental and preclinical modeling of NUP98-rearranged acute leukemia | API | |
| P30CA021765 P30FY1985–2026$336.0M | Cancer Biology (CBP) | API | |
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API | |
| U10CA098413 U10FY2003–2013$67.5M | Children's Oncology Group Statistics and Data Center Grant | API | |
| R35CA210030 R35FY2016–2022$7.3M | Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer | API | |
| U10CA180899 U10FY2014–2026$175.1M | Children's Oncology Group Statistics and Data Center | API | |
| U24CA114766 U24FY2005–2014$14.5M | Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) | API | |
| U10CA180886 U10FY2014–2026$455.4M | COG NCTN Network Group Operations Center | API | |
| U24CA196173 U24FY2015–2026$62.5M | COG U24 Funding 2026-2027 | API | |
| P30CA138292 P30FY2009–2026$85.9M | Winship Cancer Institute Cancer Center Support Grant | API | |
| U10CA180820 U10FY2014–2026$256.4M | ECOG-ACRIN Network Group Operations Center | API | |
| U24CA196172 U24FY2015–2026$41.1M | ECOG-ACRIN Biospecimen Bank to Support NCTN | API | |
| R01CA201309 R01FY2016–2020$1.7M | How HTLV-I Tax and HBZ control telomerase activity to induce adult T-cell leukemia | API | |
| P30CA008748 P30FY1985–2026$718.2M | Cancer Center Administration | API | |
| P30CA013696 P30FY1985–2026$281.2M | Cancer Center Support Grant | API | |
| R01CA179044 R01FY2014–2018$2.3M | Identification and modeling of driver genetic modules in glioblastoma | API | |
| R01CA185486 R01FY2014–2017$2.1M | (PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data | API | |
| R01CA216981 R01FY2017–2021$1.9M | Molecular characterization and targeting of NT5C2 mutations in acute lymphoblastic leukemia | API | |
| R35CA210065 R35FY2017–2021$4.7M | Molecular pathways and targeted therapies in human leukemia | API | |
| U10CA014958 U10FY1985–2013$5.2M | EASTERN COOPERATIVE ONCOLOGY GROUP | API | |
| U10CA017145 U10FY1985–2013$9.5M | ECOG Clinical Trials | API | |
| U10CA180791 U10FY2014–2018$4.6M | Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center | API | |
| U10CA180827 U10FY2014–2018$3.0M | ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER | API | |
| U54CA121852 U54FY2005–2015$72.1M | National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet) | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P30CA008748 P30FY1985–2026$718.2M | Cancer Center Administration | API |
| P30CA013696 P30FY1985–2026$281.2M | Cancer Center Support Grant | API |
| P30CA016058 P30FY1985–2026$258.1M | Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR) | API |
| P30CA021765 P30FY1985–2026$336.0M | Cancer Biology (CBP) | API |
| P30CA138292 P30FY2009–2026$85.9M | Winship Cancer Institute Cancer Center Support Grant | API |
| U01CA157937 U01FY2011–2015$2.9M | MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL | API |
| U10CA014958 U10FY1985–2013$5.2M | EASTERN COOPERATIVE ONCOLOGY GROUP | API |
| U10CA017145 U10FY1985–2013$9.5M | ECOG Clinical Trials | API |
| U10CA098413 U10FY2003–2013$67.5M | Children's Oncology Group Statistics and Data Center Grant | API |
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API |
| U10CA180791 U10FY2014–2018$4.6M | Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center | API |
| U10CA180820 U10FY2014–2026$256.4M | ECOG-ACRIN Network Group Operations Center | API |
| U10CA180827 U10FY2014–2018$3.0M | ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER | API |
| U10CA180886 U10FY2014–2026$455.4M | COG NCTN Network Group Operations Center | API |
| U10CA180899 U10FY2014–2026$175.1M | Children's Oncology Group Statistics and Data Center | API |
| U24CA114766 U24FY2005–2014$14.5M | Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) | API |
| U24CA196172 U24FY2015–2026$41.1M | ECOG-ACRIN Biospecimen Bank to Support NCTN | API |
| U24CA196173 U24FY2015–2026$62.5M | COG U24 Funding 2026-2027 | API |
| U54CA121852 U54FY2005–2015$72.1M | National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet) | API |
| U54CA243124 U54FY2019–2023$20.9M | Experimental and preclinical modeling of NUP98-rearranged acute leukemia | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.